Ivenix Infusion System Receives FDA 510(k) Clearance;
Poised to Revolutionize the Infusion Pump Industry

  • BOSTON, June 11, 2019 – The U.S. Food and Drug Administration (FDA) has issued 510(k) clearance for the Ivenix Infusion System, ushering in a new era of infusion systems designed to make infusions safer, while lowering the total cost of ownership. Ivenix looks to disrupt the $4.7 billion North American infusion market, which has been fraught with dangerous and costly errors associated with legacy technologies. The Ivenix Infusion System is the first and only large-volume pump and infusion system designed from the ground up to meet the new FDA infusion pump guidelines, adopted in 2014 to address the recurring safety problems associated with infusion pumps.Outdated technology and poor user interfaces of current infusion systems have led to persistent errors, pump recalls, cybersecurity threats and high costs. Infusion-related errors account for more than 50% of the 1.5 million adverse drug events reported annually to the FDA, and infusion-related adverse drug events account for more than $2 billion in annual healthcare costs…READ MORE

Lundbeck to acquire Abide Therapeutics, adding a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s

  • Abide’s world-class discovery platform is focused on harnessing the therapeutic potential of one of the largest and most diverse enzyme classes – the serine hydrolases (SHs) – with the potential to deliver unprecedented compounds across a broad range of central nervous system (CNS) indications
  • Abide’s lead product ABX 1431 is a first-in-class inhibitor of monoacylglycerol lipase (MGLL), modulating the endocannabinoid system. ABX-1431 is in clinical development for Tourette’s  (exploratory phase IIa) and neuropathic pain (phase I)
  • Lundbeck to acquire Abide for USD 250 million in upfront payment and with additional development and sales milestones

Valby, Denmark, San Diego, USA, 6 May 2019 – H. Lundbeck A/S (Lundbeck) and Abide Therapeutics, Inc. (Abide) today announced signing of a definitive agreement in which Lundbeck LLC has agreed to acquire Abide. Under the terms of the agreement, Lundbeck may pay USD 250 million (approximately DKK 1.65 billion) upfront with a commitment to pay future development and sales milestones to the group of current owners of up to USD 150 million (approximately DKK 1 billion). This acquisition provides Lundbeck a novel discovery platform and a U.S.-based research hub…READ MORE

double exposure image of virtual human 3dillustration on blue circuit board background represent artificial 
intelligence AI technology

Cardinal Analytx Closes $22 Million Series B Round
Round by John Doerr, GuideWell, Blue Shield California and Premera Blue Cross Will Support Accelerated Hiring and Continued Innovation to Meet Fast-Growing Customer Demand

PALO ALTO, Calif.May 23, 2019 /PRNewswire/ — Cardinal Analytx Solutions, an artificial intelligence (AI)-enabled health insights company, today announced a $22 million Series B funding round led by John Doerr, who will also serve on the Cardinal Analytx board of directors. Joining the round were strategic investors GuideWell Mutual Holding Corporation, Blue Shield California and Premera Blue Cross.

This new round of capital will enable Cardinal Analytx to rapidly extend its lead in the innovative use of machine learning to drive proactive healthcare through investments in talent and technology.

“We take great pleasure in welcoming John Doerr to our board and are honored by the investments from his family fund, our strategic health plan partners and other leading investors,” said Cardinal Analytx CEO Linda T. Hand. “The new growth funding positions us to capitalize on our early commercial traction and robust pipeline. We expect to quickly extend our leadership in the use of AI to accurately predict rising risk and future costs, and deliver actionable insights.”…



Teladoc Health Establishes First and Only Patient Safety Organization (PSO) for Virtual Care


Teladoc Health Establishes First and Only Patient Safety Organization (PSO) for Virtual Care

Listed through the Agency for Healthcare Research and Quality HHS, the PSO will develop and execute industry-leading quality and safety initiatives

PURCHASE, NY – May 20, 2019 –Teladoc Health (NYSE: TDOC), the global leader in virtual care, announces that it has established the healthcare industry’s first Patient Safety Organization (PSO) dedicated to virtual care. Listed and certified by the Agency for Healthcare Research and Quality(AHRQ) effective May 8, 2019, this newly formed component entity of Teladoc Health is formally recognized by the Department of Health and Human Services (HHS) as The Institute for Patient Safety and Quality of Virtual Care. The organization will conduct quality and safety initiatives with and on behalf of key healthcare stakeholders, including other PSOs, to improve the delivery of virtual care across the country.

“The establishment of the first PSO focused on virtual care is a significant benefit to the healthcare industry at large and a testament to Teladoc Health’s unwavering commitment to quality care and improved health outcomes,” said Jason Tibbels, M.D., vice president of health services for Teladoc Health and president of the Institute for Patient Safety and Quality of Virtual Care. “As virtual care increasingly becomes the front door for patients and providers alike, we continue to leverage our experience of effectively working with the broader healthcare system while we set the bar for quality.”



Vitals Announces Company Name Change to Sapphire Digital

FEBRUARY 20, 2019 – LYNDHURST, N.J. – Vitals announces that we are changing our name to Sapphire Digital. The new name reflects our leadership in providing a full omnichannel digital engagement and shopping platform for consumers, employers and health plans to impact the cycle of high-cost health care…. READ MORE

Scroll to top